New Mexico Cancer Research Alliance
Quick facts
Phase 3 pipeline
- Gemcitabine and Oxaliplatin · Oncology
Gemcitabine and oxaliplatin work together as a chemotherapy combination to damage cancer cell DNA and prevent cell division through complementary mechanisms. - paclitaxel, docetaxel, taxane
Phase 2 pipeline
- Aprepitant vs. Gabapentin · Oncology
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting. - Gleevec and Arsenic Trioxide · Oncology
Tyrosine kinase inhibitor - Irinotecan, oxaliplatin, and cetuximab
- Progesterone Only Hormone Replacement Therapy
Phase 1 pipeline
- Erlotinib PO and Vidaza IV
- Gemcitabine, Docetaxel and Bevacizumab
- Hydralazine and Valproic Acid: Cohort -1
- raltegravir and cisplatin
- Topotecan and VP16
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- New Mexico Cancer Research Alliance portfolio CI brief
- New Mexico Cancer Research Alliance pipeline updates RSS
Frequently asked questions about New Mexico Cancer Research Alliance
What is New Mexico Cancer Research Alliance's pipeline?
New Mexico Cancer Research Alliance has 2 drugs in Phase 3, 4 in Phase 2, 5 in Phase 1. Late-stage candidates include Gemcitabine and Oxaliplatin, paclitaxel, docetaxel, taxane.
Related
- Sector hub: All tracked pharma companies